Extract
Non-infectious pulmonary complications are frequent after allogeneic haematopoietic stem cell transplantation (HSCT). They are mainly represented by bronchiolitis obliterans and interstitial pneumonia in the setting of chronic graft-versus-host disease (cGVHD) (1).
Abstract
Ruxolitinib may induce pulmonary alveolar proteinosis and favour respiratory non-tuberculous mycobacterial infections.
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: Dr. SALVATOR reports non-financial support from Oxyvie, grants from LVL medical, grants from Cardif assistance, non-financial support from Boehringer, outside the submitted work.
Conflict of interest: Dr. BERTI has nothing to disclose.
Conflict of interest: Dr. Catherinot reports non-financial support from LVL medical, non-financial support from CSL Behring, outside the submitted work.
Conflict of interest: Dr. RIVAUD reports non-financial support from Chiesi, non-financial support from Boehringer, outside the submitted work.
Conflict of interest: Dr. Chabrol reports non-financial support from Homeperf, non-financial support from LVL medical, non-financial support from Roche, outside the submitted work.
Conflict of interest: Dr. NGUYEN has nothing to disclose.
Conflict of interest: Dr. Zemoura has nothing to disclose.
Conflict of interest: Dr. CARDOT has nothing to disclose.
Conflict of interest: Dr. TCHERAKIAN reports personal fees and non-financial support from novartis, personal fees and non-financial support from boehringer, personal fees and non-financial support from chiesi, outside the submitted work.
Conflict of interest: Dr. Couderc reports personal fees and non-financial support from Boehringer Ingelheim, grants and personal fees from Novartis, grants from LVL, non-financial support from Teva, grants from ZAMS, outside the submitted work.
- Copyright ©ERS 2018